nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—FGFR2—prostate cancer	0.134	0.358	CbGaD
Regorafenib—PDGFRB—prostate cancer	0.106	0.283	CbGaD
Regorafenib—KDR—prostate cancer	0.0802	0.214	CbGaD
Regorafenib—CYP2C19—prostate cancer	0.033	0.0881	CbGaD
Regorafenib—CYP3A4—prostate cancer	0.021	0.056	CbGaD
Regorafenib—UGT1A1—Estradiol—prostate cancer	0.0155	0.0474	CbGbCtD
Regorafenib—ABCG2—Cabazitaxel—prostate cancer	0.0152	0.0465	CbGbCtD
Regorafenib—ABCG2—Estrone—prostate cancer	0.0148	0.0454	CbGbCtD
Regorafenib—CYP2C8—Nilutamide—prostate cancer	0.0132	0.0404	CbGbCtD
Regorafenib—CYP2C19—Bicalutamide—prostate cancer	0.0111	0.0339	CbGbCtD
Regorafenib—CYP2C19—Nilutamide—prostate cancer	0.0111	0.0339	CbGbCtD
Regorafenib—CYP2C8—Abiraterone—prostate cancer	0.0109	0.0335	CbGbCtD
Regorafenib—CYP2B6—Estrone—prostate cancer	0.0104	0.0319	CbGbCtD
Regorafenib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0102	0.0312	CbGbCtD
Regorafenib—UGT1A1—Etoposide—prostate cancer	0.0101	0.031	CbGbCtD
Regorafenib—ABCG2—Conjugated Estrogens—prostate cancer	0.00969	0.0297	CbGbCtD
Regorafenib—CYP2B6—Ethinyl Estradiol—prostate cancer	0.00929	0.0285	CbGbCtD
Regorafenib—CYP2C9—Nilutamide—prostate cancer	0.00919	0.0282	CbGbCtD
Regorafenib—CYP2C9—Bicalutamide—prostate cancer	0.00919	0.0282	CbGbCtD
Regorafenib—CYP2C19—Flutamide—prostate cancer	0.00916	0.0281	CbGbCtD
Regorafenib—ABCG2—Mitoxantrone—prostate cancer	0.00881	0.027	CbGbCtD
Regorafenib—ABCG2—Estradiol—prostate cancer	0.00851	0.0261	CbGbCtD
Regorafenib—ABCB1—Estramustine—prostate cancer	0.00829	0.0254	CbGbCtD
Regorafenib—CYP2C8—Cabazitaxel—prostate cancer	0.00807	0.0247	CbGbCtD
Regorafenib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00703	0.0216	CbGbCtD
Regorafenib—ABCG2—Etoposide—prostate cancer	0.00556	0.017	CbGbCtD
Regorafenib—CYP2C9—Estrone—prostate cancer	0.0055	0.0169	CbGbCtD
Regorafenib—ABCB1—Cabazitaxel—prostate cancer	0.00547	0.0167	CbGbCtD
Regorafenib—CYP3A4—Bicalutamide—prostate cancer	0.00534	0.0164	CbGbCtD
Regorafenib—ABCB1—Estrone—prostate cancer	0.00534	0.0164	CbGbCtD
Regorafenib—ABCG2—Docetaxel—prostate cancer	0.00508	0.0156	CbGbCtD
Regorafenib—CYP3A4—Estramustine—prostate cancer	0.00497	0.0152	CbGbCtD
Regorafenib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00476	0.0146	CbGbCtD
Regorafenib—CYP2C8—Estradiol—prostate cancer	0.00453	0.0139	CbGbCtD
Regorafenib—CYP3A4—Flutamide—prostate cancer	0.00443	0.0136	CbGbCtD
Regorafenib—CYP3A4—Abiraterone—prostate cancer	0.00443	0.0136	CbGbCtD
Regorafenib—CYP2C9—Capecitabine—prostate cancer	0.00417	0.0128	CbGbCtD
Regorafenib—CYP2C19—Estradiol—prostate cancer	0.0038	0.0117	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—prostate cancer	0.00379	0.0116	CbGbCtD
Regorafenib—ABCB1—Conjugated Estrogens—prostate cancer	0.00349	0.0107	CbGbCtD
Regorafenib—CYP3A4—Cabazitaxel—prostate cancer	0.00327	0.01	CbGbCtD
Regorafenib—CYP2C19—Prednisone—prostate cancer	0.00327	0.01	CbGbCtD
Regorafenib—CYP3A4—Estrone—prostate cancer	0.0032	0.00981	CbGbCtD
Regorafenib—ABCB1—Mitoxantrone—prostate cancer	0.00318	0.00974	CbGbCtD
Regorafenib—CYP2C9—Estradiol—prostate cancer	0.00316	0.00969	CbGbCtD
Regorafenib—ABCB1—Estradiol—prostate cancer	0.00307	0.0094	CbGbCtD
Regorafenib—CYP2C8—Etoposide—prostate cancer	0.00296	0.00907	CbGbCtD
Regorafenib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00285	0.00874	CbGbCtD
Regorafenib—PDGFRA—penis—prostate cancer	0.00273	0.0467	CbGeAlD
Regorafenib—CYP2B6—Doxorubicin—prostate cancer	0.00266	0.00817	CbGbCtD
Regorafenib—ABCB1—Prednisone—prostate cancer	0.00264	0.00809	CbGbCtD
Regorafenib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00209	0.00642	CbGbCtD
Regorafenib—ABCB1—Etoposide—prostate cancer	0.002	0.00614	CbGbCtD
Regorafenib—CYP3A4—Mitoxantrone—prostate cancer	0.0019	0.00583	CbGbCtD
Regorafenib—CYP3A4—Estradiol—prostate cancer	0.00184	0.00563	CbGbCtD
Regorafenib—ABCB1—Docetaxel—prostate cancer	0.00183	0.00562	CbGbCtD
Regorafenib—UGT1A1—urine—prostate cancer	0.00173	0.0297	CbGeAlD
Regorafenib—CYP3A4—Prednisone—prostate cancer	0.00158	0.00484	CbGbCtD
Regorafenib—DDR2—prostate gland—prostate cancer	0.00147	0.0251	CbGeAlD
Regorafenib—MAPK11—prostate gland—prostate cancer	0.00139	0.0238	CbGeAlD
Regorafenib—ABCB1—Doxorubicin—prostate cancer	0.00137	0.00419	CbGbCtD
Regorafenib—CYP3A4—Etoposide—prostate cancer	0.0012	0.00368	CbGbCtD
Regorafenib—FRK—renal system—prostate cancer	0.00112	0.0191	CbGeAlD
Regorafenib—CYP3A4—Docetaxel—prostate cancer	0.0011	0.00337	CbGbCtD
Regorafenib—Sorafenib—MAP3K7—prostate cancer	0.00109	0.311	CrCbGaD
Regorafenib—BRAF—prostate gland—prostate cancer	0.00104	0.0178	CbGeAlD
Regorafenib—EPHX2—prostate gland—prostate cancer	0.000992	0.017	CbGeAlD
Regorafenib—CYP2C19—urine—prostate cancer	0.000939	0.0161	CbGeAlD
Regorafenib—Sorafenib—RALBP1—prostate cancer	0.00093	0.264	CrCbGaD
Regorafenib—FLT4—prostate gland—prostate cancer	0.000895	0.0153	CbGeAlD
Regorafenib—FGFR1—prostate gland—prostate cancer	0.000883	0.0151	CbGeAlD
Regorafenib—NTRK1—testis—prostate cancer	0.00087	0.0149	CbGeAlD
Regorafenib—EPHX2—seminal vesicle—prostate cancer	0.000839	0.0144	CbGeAlD
Regorafenib—CYP3A4—Doxorubicin—prostate cancer	0.000819	0.00251	CbGbCtD
Regorafenib—RET—prostate gland—prostate cancer	0.00079	0.0135	CbGeAlD
Regorafenib—FGFR2—prostate gland—prostate cancer	0.00075	0.0128	CbGeAlD
Regorafenib—EPHA2—prostate gland—prostate cancer	0.000737	0.0126	CbGeAlD
Regorafenib—CYP2C9—urine—prostate cancer	0.000728	0.0125	CbGeAlD
Regorafenib—FRK—testis—prostate cancer	0.000721	0.0123	CbGeAlD
Regorafenib—TEK—prostate gland—prostate cancer	0.000719	0.0123	CbGeAlD
Regorafenib—FLT1—prostate gland—prostate cancer	0.000696	0.0119	CbGeAlD
Regorafenib—RAF1—prostate gland—prostate cancer	0.000692	0.0118	CbGeAlD
Regorafenib—EPHX2—urethra—prostate cancer	0.000664	0.0114	CbGeAlD
Regorafenib—FLT4—epithelium—prostate cancer	0.000657	0.0113	CbGeAlD
Regorafenib—PDGFRA—prostate gland—prostate cancer	0.000652	0.0112	CbGeAlD
Regorafenib—DDR2—testis—prostate cancer	0.000647	0.0111	CbGeAlD
Regorafenib—EPHA2—seminal vesicle—prostate cancer	0.000624	0.0107	CbGeAlD
Regorafenib—UGT1A1—prostate gland—prostate cancer	0.000622	0.0106	CbGeAlD
Regorafenib—UGT1A9—renal system—prostate cancer	0.000618	0.0106	CbGeAlD
Regorafenib—MAPK11—testis—prostate cancer	0.000613	0.0105	CbGeAlD
Regorafenib—FGFR1—urethra—prostate cancer	0.000591	0.0101	CbGeAlD
Regorafenib—FLT1—seminal vesicle—prostate cancer	0.000588	0.0101	CbGeAlD
Regorafenib—KDR—prostate gland—prostate cancer	0.000588	0.0101	CbGeAlD
Regorafenib—RAF1—seminal vesicle—prostate cancer	0.000585	0.01	CbGeAlD
Regorafenib—RET—epithelium—prostate cancer	0.00058	0.00993	CbGeAlD
Regorafenib—CYP3A4—urine—prostate cancer	0.000555	0.0095	CbGeAlD
Regorafenib—FGFR2—epithelium—prostate cancer	0.000551	0.00944	CbGeAlD
Regorafenib—Sorafenib—PDGFRB—prostate cancer	0.000548	0.156	CrCbGaD
Regorafenib—EPHA2—epithelium—prostate cancer	0.000542	0.00928	CbGeAlD
Regorafenib—RET—renal system—prostate cancer	0.000538	0.00921	CbGeAlD
Regorafenib—BRAF—bone marrow—prostate cancer	0.000535	0.00916	CbGeAlD
Regorafenib—TEK—epithelium—prostate cancer	0.000529	0.00905	CbGeAlD
Regorafenib—KIT—prostate gland—prostate cancer	0.000521	0.00892	CbGeAlD
Regorafenib—FGFR2—renal system—prostate cancer	0.000511	0.00876	CbGeAlD
Regorafenib—FLT1—epithelium—prostate cancer	0.000511	0.00875	CbGeAlD
Regorafenib—PDGFRB—prostate gland—prostate cancer	0.000509	0.00871	CbGeAlD
Regorafenib—RAF1—epithelium—prostate cancer	0.000508	0.0087	CbGeAlD
Regorafenib—KDR—seminal vesicle—prostate cancer	0.000497	0.00851	CbGeAlD
Regorafenib—EPHA2—urethra—prostate cancer	0.000494	0.00845	CbGeAlD
Regorafenib—TEK—renal system—prostate cancer	0.00049	0.00839	CbGeAlD
Regorafenib—TEK—urethra—prostate cancer	0.000482	0.00825	CbGeAlD
Regorafenib—FLT1—renal system—prostate cancer	0.000474	0.00812	CbGeAlD
Regorafenib—RAF1—renal system—prostate cancer	0.000471	0.00807	CbGeAlD
Regorafenib—DDR2—lymph node—prostate cancer	0.000469	0.00803	CbGeAlD
Regorafenib—FLT1—urethra—prostate cancer	0.000466	0.00797	CbGeAlD
Regorafenib—RAF1—urethra—prostate cancer	0.000463	0.00793	CbGeAlD
Regorafenib—FLT4—bone marrow—prostate cancer	0.000461	0.00789	CbGeAlD
Regorafenib—BRAF—testis—prostate cancer	0.000457	0.00783	CbGeAlD
Regorafenib—ABL1—prostate gland—prostate cancer	0.000454	0.00776	CbGeAlD
Regorafenib—FGFR2—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000447	0.191	CbGdCrCtD
Regorafenib—MAPK11—lymph node—prostate cancer	0.000445	0.00761	CbGeAlD
Regorafenib—PDGFRA—renal system—prostate cancer	0.000444	0.0076	CbGeAlD
Regorafenib—KIT—seminal vesicle—prostate cancer	0.000441	0.00754	CbGeAlD
Regorafenib—EPHX2—testis—prostate cancer	0.000437	0.00748	CbGeAlD
Regorafenib—KDR—epithelium—prostate cancer	0.000432	0.0074	CbGeAlD
Regorafenib—PDGFRB—seminal vesicle—prostate cancer	0.00043	0.00737	CbGeAlD
Regorafenib—UGT1A1—renal system—prostate cancer	0.000424	0.00725	CbGeAlD
Regorafenib—Sorafenib—KDR—prostate cancer	0.000416	0.118	CrCbGaD
Regorafenib—KDR—renal system—prostate cancer	0.000401	0.00686	CbGeAlD
Regorafenib—FLT4—testis—prostate cancer	0.000394	0.00675	CbGeAlD
Regorafenib—KDR—urethra—prostate cancer	0.000394	0.00674	CbGeAlD
Regorafenib—FGFR1—testis—prostate cancer	0.000389	0.00666	CbGeAlD
Regorafenib—ABL1—seminal vesicle—prostate cancer	0.000384	0.00657	CbGeAlD
Regorafenib—KIT—epithelium—prostate cancer	0.000383	0.00655	CbGeAlD
Regorafenib—FGFR2—Estradiol—Estramustine—prostate cancer	0.00038	0.162	CbGdCrCtD
Regorafenib—PDGFRB—epithelium—prostate cancer	0.000374	0.0064	CbGeAlD
Regorafenib—RAF1—bone marrow—prostate cancer	0.000356	0.0061	CbGeAlD
Regorafenib—KIT—renal system—prostate cancer	0.000355	0.00608	CbGeAlD
Regorafenib—KIT—urethra—prostate cancer	0.000349	0.00597	CbGeAlD
Regorafenib—RET—testis—prostate cancer	0.000348	0.00596	CbGeAlD
Regorafenib—PDGFRB—renal system—prostate cancer	0.000347	0.00594	CbGeAlD
Regorafenib—PDGFRB—urethra—prostate cancer	0.000341	0.00583	CbGeAlD
Regorafenib—BRAF—lymph node—prostate cancer	0.000331	0.00567	CbGeAlD
Regorafenib—FGFR2—testis—prostate cancer	0.000331	0.00566	CbGeAlD
Regorafenib—EPHA2—testis—prostate cancer	0.000325	0.00556	CbGeAlD
Regorafenib—TEK—testis—prostate cancer	0.000317	0.00543	CbGeAlD
Regorafenib—EPHX2—lymph node—prostate cancer	0.000317	0.00542	CbGeAlD
Regorafenib—ABL1—renal system—prostate cancer	0.000309	0.00529	CbGeAlD
Regorafenib—FLT1—testis—prostate cancer	0.000306	0.00525	CbGeAlD
Regorafenib—RAF1—testis—prostate cancer	0.000305	0.00521	CbGeAlD
Regorafenib—ABL1—urethra—prostate cancer	0.000304	0.0052	CbGeAlD
Regorafenib—KDR—bone marrow—prostate cancer	0.000303	0.00519	CbGeAlD
Regorafenib—FGFR2—Estradiol—Estrone—prostate cancer	0.000302	0.129	CbGdCrCtD
Regorafenib—PDGFRA—testis—prostate cancer	0.000287	0.00492	CbGeAlD
Regorafenib—ABCG2—prostate gland—prostate cancer	0.000286	0.0049	CbGeAlD
Regorafenib—FLT4—lymph node—prostate cancer	0.000286	0.00489	CbGeAlD
Regorafenib—FGFR1—lymph node—prostate cancer	0.000282	0.00482	CbGeAlD
Regorafenib—KIT—bone marrow—prostate cancer	0.000269	0.0046	CbGeAlD
Regorafenib—FGFR2—Estradiol—Conjugated Estrogens—prostate cancer	0.000266	0.114	CbGdCrCtD
Regorafenib—PDGFRB—bone marrow—prostate cancer	0.000262	0.00449	CbGeAlD
Regorafenib—KDR—testis—prostate cancer	0.000259	0.00443	CbGeAlD
Regorafenib—RET—lymph node—prostate cancer	0.000252	0.00432	CbGeAlD
Regorafenib—Sorafenib—CYP3A5—prostate cancer	0.000251	0.0713	CrCbGaD
Regorafenib—ABCG2—seminal vesicle—prostate cancer	0.000242	0.00414	CbGeAlD
Regorafenib—EPHA2—lymph node—prostate cancer	0.000235	0.00403	CbGeAlD
Regorafenib—ABL1—bone marrow—prostate cancer	0.000234	0.004	CbGeAlD
Regorafenib—TEK—lymph node—prostate cancer	0.00023	0.00393	CbGeAlD
Regorafenib—KIT—testis—prostate cancer	0.00023	0.00393	CbGeAlD
Regorafenib—PDGFRB—testis—prostate cancer	0.000224	0.00384	CbGeAlD
Regorafenib—FGFR2—Estradiol—Ethinyl Estradiol—prostate cancer	0.000223	0.0955	CbGdCrCtD
Regorafenib—FLT1—lymph node—prostate cancer	0.000222	0.0038	CbGeAlD
Regorafenib—RAF1—lymph node—prostate cancer	0.000221	0.00378	CbGeAlD
Regorafenib—PDGFRA—lymph node—prostate cancer	0.000208	0.00356	CbGeAlD
Regorafenib—CYP2C8—renal system—prostate cancer	0.000201	0.00343	CbGeAlD
Regorafenib—ABL1—testis—prostate cancer	0.0002	0.00342	CbGeAlD
Regorafenib—ABCG2—urethra—prostate cancer	0.000192	0.00328	CbGeAlD
Regorafenib—KDR—lymph node—prostate cancer	0.000188	0.00321	CbGeAlD
Regorafenib—CYP2B6—renal system—prostate cancer	0.00018	0.00308	CbGeAlD
Regorafenib—Sorafenib—CYP2C19—prostate cancer	0.000171	0.0485	CrCbGaD
Regorafenib—KIT—lymph node—prostate cancer	0.000166	0.00285	CbGeAlD
Regorafenib—PDGFRB—lymph node—prostate cancer	0.000163	0.00278	CbGeAlD
Regorafenib—ABL1—Levorphanol—Estrone—prostate cancer	0.00015	0.0642	CbGdCrCtD
Regorafenib—ABCG2—bone marrow—prostate cancer	0.000147	0.00252	CbGeAlD
Regorafenib—ABL1—lymph node—prostate cancer	0.000145	0.00248	CbGeAlD
Regorafenib—ABCB1—prostate gland—prostate cancer	0.000141	0.00241	CbGeAlD
Regorafenib—CYP3A4—renal system—prostate cancer	0.000136	0.00232	CbGeAlD
Regorafenib—CYP2C8—testis—prostate cancer	0.00013	0.00222	CbGeAlD
Regorafenib—ABCG2—testis—prostate cancer	0.000126	0.00216	CbGeAlD
Regorafenib—ABCB1—seminal vesicle—prostate cancer	0.000119	0.00204	CbGeAlD
Regorafenib—CYP2B6—testis—prostate cancer	0.000116	0.00199	CbGeAlD
Regorafenib—ABL1—Levorphanol—Estradiol—prostate cancer	0.000114	0.0487	CbGdCrCtD
Regorafenib—Sorafenib—CYP3A4—prostate cancer	0.000109	0.0308	CrCbGaD
Regorafenib—ABCB1—epithelium—prostate cancer	0.000104	0.00177	CbGeAlD
Regorafenib—ABCB1—renal system—prostate cancer	9.61e-05	0.00165	CbGeAlD
Regorafenib—ABCB1—urethra—prostate cancer	9.44e-05	0.00162	CbGeAlD
Regorafenib—ABCG2—lymph node—prostate cancer	9.13e-05	0.00156	CbGeAlD
Regorafenib—ABL1—Idarubicin—Epirubicin—prostate cancer	7.9e-05	0.0338	CbGdCrCtD
Regorafenib—ABL1—Doxorubicin—Epirubicin—prostate cancer	7.9e-05	0.0338	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—prostate cancer	7.9e-05	0.0338	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—prostate cancer	7.31e-05	0.0313	CbGdCrCtD
Regorafenib—ABL1—Epirubicin—Doxorubicin—prostate cancer	7.31e-05	0.0313	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	7.31e-05	0.0313	CbGdCrCtD
Regorafenib—ABCB1—bone marrow—prostate cancer	7.27e-05	0.00124	CbGeAlD
Regorafenib—Skin disorder—Mitoxantrone—prostate cancer	6.67e-05	0.00066	CcSEcCtD
Regorafenib—Asthenia—Conjugated Estrogens—prostate cancer	6.6e-05	0.000654	CcSEcCtD
Regorafenib—Urinary tract disorder—Docetaxel—prostate cancer	6.6e-05	0.000653	CcSEcCtD
Regorafenib—Connective tissue disorder—Docetaxel—prostate cancer	6.56e-05	0.00065	CcSEcCtD
Regorafenib—Urethral disorder—Docetaxel—prostate cancer	6.55e-05	0.000648	CcSEcCtD
Regorafenib—Hyponatraemia—Epirubicin—prostate cancer	6.54e-05	0.000648	CcSEcCtD
Regorafenib—Weight decreased—Prednisone—prostate cancer	6.51e-05	0.000645	CcSEcCtD
Regorafenib—Haemoglobin—Capecitabine—prostate cancer	6.5e-05	0.000644	CcSEcCtD
Regorafenib—Haemorrhage—Capecitabine—prostate cancer	6.47e-05	0.00064	CcSEcCtD
Regorafenib—Anaemia—Etoposide—prostate cancer	6.47e-05	0.00064	CcSEcCtD
Regorafenib—Decreased appetite—Estradiol—prostate cancer	6.4e-05	0.000634	CcSEcCtD
Regorafenib—Urinary tract disorder—Capecitabine—prostate cancer	6.39e-05	0.000633	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Estradiol—prostate cancer	6.36e-05	0.00063	CcSEcCtD
Regorafenib—Diarrhoea—Goserelin—prostate cancer	6.36e-05	0.00063	CcSEcCtD
Regorafenib—Connective tissue disorder—Capecitabine—prostate cancer	6.35e-05	0.000629	CcSEcCtD
Regorafenib—Fatigue—Estradiol—prostate cancer	6.35e-05	0.000629	CcSEcCtD
Regorafenib—Urethral disorder—Capecitabine—prostate cancer	6.34e-05	0.000628	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisone—prostate cancer	6.32e-05	0.000626	CcSEcCtD
Regorafenib—Erythema multiforme—Docetaxel—prostate cancer	6.31e-05	0.000625	CcSEcCtD
Regorafenib—Pain—Estradiol—prostate cancer	6.3e-05	0.000624	CcSEcCtD
Regorafenib—Diarrhoea—Conjugated Estrogens—prostate cancer	6.3e-05	0.000624	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisone—prostate cancer	6.29e-05	0.000623	CcSEcCtD
Regorafenib—Leukopenia—Etoposide—prostate cancer	6.26e-05	0.00062	CcSEcCtD
Regorafenib—ABCB1—testis—prostate cancer	6.21e-05	0.00106	CbGeAlD
Regorafenib—Cardiac disorder—Docetaxel—prostate cancer	6.2e-05	0.000614	CcSEcCtD
Regorafenib—Erythema multiforme—Capecitabine—prostate cancer	6.11e-05	0.000606	CcSEcCtD
Regorafenib—Angiopathy—Docetaxel—prostate cancer	6.06e-05	0.0006	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—prostate cancer	6.05e-05	0.000599	CcSEcCtD
Regorafenib—Hypertension—Etoposide—prostate cancer	6.04e-05	0.000598	CcSEcCtD
Regorafenib—Gastrointestinal pain—Estradiol—prostate cancer	6.02e-05	0.000597	CcSEcCtD
Regorafenib—Mediastinal disorder—Docetaxel—prostate cancer	6.02e-05	0.000596	CcSEcCtD
Regorafenib—Cardiac disorder—Capecitabine—prostate cancer	6e-05	0.000594	CcSEcCtD
Regorafenib—Dry skin—Epirubicin—prostate cancer	5.97e-05	0.000591	CcSEcCtD
Regorafenib—Decreased appetite—Mitoxantrone—prostate cancer	5.97e-05	0.000591	CcSEcCtD
Regorafenib—Hypokalaemia—Epirubicin—prostate cancer	5.93e-05	0.000587	CcSEcCtD
Regorafenib—Fatigue—Mitoxantrone—prostate cancer	5.92e-05	0.000586	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	5.91e-05	0.000586	CcSEcCtD
Regorafenib—Vomiting—Goserelin—prostate cancer	5.91e-05	0.000585	CcSEcCtD
Regorafenib—Alopecia—Docetaxel—prostate cancer	5.9e-05	0.000585	CcSEcCtD
Regorafenib—Pain—Mitoxantrone—prostate cancer	5.87e-05	0.000581	CcSEcCtD
Regorafenib—Angiopathy—Capecitabine—prostate cancer	5.87e-05	0.000581	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Epirubicin—prostate cancer	5.86e-05	0.000581	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Epirubicin—prostate cancer	5.86e-05	0.000581	CcSEcCtD
Regorafenib—Rash—Goserelin—prostate cancer	5.86e-05	0.00058	CcSEcCtD
Regorafenib—Dermatitis—Goserelin—prostate cancer	5.85e-05	0.00058	CcSEcCtD
Regorafenib—Vomiting—Conjugated Estrogens—prostate cancer	5.85e-05	0.00058	CcSEcCtD
Regorafenib—Mediastinal disorder—Capecitabine—prostate cancer	5.83e-05	0.000577	CcSEcCtD
Regorafenib—Abdominal pain—Estradiol—prostate cancer	5.82e-05	0.000577	CcSEcCtD
Regorafenib—Body temperature increased—Estradiol—prostate cancer	5.82e-05	0.000577	CcSEcCtD
Regorafenib—Headache—Goserelin—prostate cancer	5.82e-05	0.000577	CcSEcCtD
Regorafenib—Malnutrition—Docetaxel—prostate cancer	5.81e-05	0.000576	CcSEcCtD
Regorafenib—Rash—Conjugated Estrogens—prostate cancer	5.8e-05	0.000575	CcSEcCtD
Regorafenib—Dermatitis—Conjugated Estrogens—prostate cancer	5.8e-05	0.000574	CcSEcCtD
Regorafenib—Haemoglobin—Prednisone—prostate cancer	5.79e-05	0.000573	CcSEcCtD
Regorafenib—Headache—Conjugated Estrogens—prostate cancer	5.77e-05	0.000571	CcSEcCtD
Regorafenib—Haemorrhage—Prednisone—prostate cancer	5.76e-05	0.000571	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Epirubicin—prostate cancer	5.74e-05	0.000569	CcSEcCtD
Regorafenib—Alopecia—Capecitabine—prostate cancer	5.71e-05	0.000566	CcSEcCtD
Regorafenib—Infection—Etoposide—prostate cancer	5.67e-05	0.000562	CcSEcCtD
Regorafenib—Connective tissue disorder—Prednisone—prostate cancer	5.66e-05	0.000561	CcSEcCtD
Regorafenib—Malnutrition—Capecitabine—prostate cancer	5.63e-05	0.000558	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mitoxantrone—prostate cancer	5.61e-05	0.000556	CcSEcCtD
Regorafenib—Thrombocytopenia—Etoposide—prostate cancer	5.59e-05	0.000554	CcSEcCtD
Regorafenib—Skin disorder—Etoposide—prostate cancer	5.55e-05	0.000549	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—prostate cancer	5.52e-05	0.000547	CcSEcCtD
Regorafenib—Nausea—Goserelin—prostate cancer	5.52e-05	0.000547	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—prostate cancer	5.48e-05	0.000543	CcSEcCtD
Regorafenib—Nausea—Conjugated Estrogens—prostate cancer	5.47e-05	0.000542	CcSEcCtD
Regorafenib—Body temperature increased—Mitoxantrone—prostate cancer	5.43e-05	0.000537	CcSEcCtD
Regorafenib—Abdominal pain—Mitoxantrone—prostate cancer	5.43e-05	0.000537	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	5.43e-05	0.000537	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	5.43e-05	0.000537	CcSEcCtD
Regorafenib—Anaemia—Docetaxel—prostate cancer	5.37e-05	0.000532	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—prostate cancer	5.31e-05	0.000526	CcSEcCtD
Regorafenib—Asthenia—Estradiol—prostate cancer	5.29e-05	0.000524	CcSEcCtD
Regorafenib—Tremor—Capecitabine—prostate cancer	5.27e-05	0.000522	CcSEcCtD
Regorafenib—Neutropenia—Epirubicin—prostate cancer	5.26e-05	0.000521	CcSEcCtD
Regorafenib—Angiopathy—Prednisone—prostate cancer	5.23e-05	0.000518	CcSEcCtD
Regorafenib—Leukopenia—Docetaxel—prostate cancer	5.2e-05	0.000515	CcSEcCtD
Regorafenib—Anaemia—Capecitabine—prostate cancer	5.2e-05	0.000515	CcSEcCtD
Regorafenib—Weight decreased—Epirubicin—prostate cancer	5.09e-05	0.000504	CcSEcCtD
Regorafenib—Alopecia—Prednisone—prostate cancer	5.09e-05	0.000504	CcSEcCtD
Regorafenib—Diarrhoea—Estradiol—prostate cancer	5.04e-05	0.000499	CcSEcCtD
Regorafenib—Leukopenia—Capecitabine—prostate cancer	5.04e-05	0.000499	CcSEcCtD
Regorafenib—Hypertension—Docetaxel—prostate cancer	5.02e-05	0.000497	CcSEcCtD
Regorafenib—Infestation—Epirubicin—prostate cancer	5.02e-05	0.000497	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—prostate cancer	5.02e-05	0.000497	CcSEcCtD
Regorafenib—Malnutrition—Prednisone—prostate cancer	5.01e-05	0.000497	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—prostate cancer	4.97e-05	0.000493	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—prostate cancer	4.96e-05	0.000492	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Etoposide—prostate cancer	4.93e-05	0.000488	CcSEcCtD
Regorafenib—Asthenia—Mitoxantrone—prostate cancer	4.92e-05	0.000488	CcSEcCtD
Regorafenib—Fatigue—Etoposide—prostate cancer	4.92e-05	0.000488	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	4.92e-05	0.000487	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—prostate cancer	4.89e-05	0.000484	CcSEcCtD
Regorafenib—Pain—Etoposide—prostate cancer	4.88e-05	0.000484	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—prostate cancer	4.87e-05	0.000482	CcSEcCtD
Regorafenib—Hypertension—Capecitabine—prostate cancer	4.86e-05	0.000481	CcSEcCtD
Regorafenib—Dry mouth—Docetaxel—prostate cancer	4.84e-05	0.000479	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	4.76e-05	0.000471	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—prostate cancer	4.75e-05	0.00047	CcSEcCtD
Regorafenib—Infection—Docetaxel—prostate cancer	4.71e-05	0.000467	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—prostate cancer	4.71e-05	0.000467	CcSEcCtD
Regorafenib—Diarrhoea—Mitoxantrone—prostate cancer	4.7e-05	0.000465	CcSEcCtD
Regorafenib—Dry mouth—Capecitabine—prostate cancer	4.69e-05	0.000464	CcSEcCtD
Regorafenib—Vomiting—Estradiol—prostate cancer	4.68e-05	0.000464	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—prostate cancer	4.67e-05	0.000462	CcSEcCtD
Regorafenib—Nervous system disorder—Docetaxel—prostate cancer	4.65e-05	0.000461	CcSEcCtD
Regorafenib—Thrombocytopenia—Docetaxel—prostate cancer	4.65e-05	0.00046	CcSEcCtD
Regorafenib—Rash—Estradiol—prostate cancer	4.64e-05	0.00046	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—prostate cancer	4.64e-05	0.00046	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—prostate cancer	4.64e-05	0.00046	CcSEcCtD
Regorafenib—Dermatitis—Estradiol—prostate cancer	4.64e-05	0.00046	CcSEcCtD
Regorafenib—Anaemia—Prednisone—prostate cancer	4.63e-05	0.000459	CcSEcCtD
Regorafenib—Headache—Estradiol—prostate cancer	4.61e-05	0.000457	CcSEcCtD
Regorafenib—Skin disorder—Docetaxel—prostate cancer	4.61e-05	0.000457	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	4.6e-05	0.000456	CcSEcCtD
Regorafenib—Infection—Capecitabine—prostate cancer	4.56e-05	0.000452	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—prostate cancer	4.53e-05	0.000448	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—prostate cancer	4.53e-05	0.000448	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—prostate cancer	4.51e-05	0.000447	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—prostate cancer	4.51e-05	0.000447	CcSEcCtD
Regorafenib—Nervous system disorder—Capecitabine—prostate cancer	4.51e-05	0.000446	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—prostate cancer	4.5e-05	0.000446	CcSEcCtD
Regorafenib—ABCB1—lymph node—prostate cancer	4.5e-05	0.000771	CbGeAlD
Regorafenib—Thrombocytopenia—Capecitabine—prostate cancer	4.5e-05	0.000446	CcSEcCtD
Regorafenib—Skin disorder—Capecitabine—prostate cancer	4.46e-05	0.000442	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—prostate cancer	4.45e-05	0.000441	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—prostate cancer	4.43e-05	0.000438	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—prostate cancer	4.42e-05	0.000437	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—prostate cancer	4.39e-05	0.000435	CcSEcCtD
Regorafenib—Nausea—Estradiol—prostate cancer	4.38e-05	0.000433	CcSEcCtD
Regorafenib—Vomiting—Mitoxantrone—prostate cancer	4.36e-05	0.000432	CcSEcCtD
Regorafenib—Hypertension—Prednisone—prostate cancer	4.33e-05	0.000429	CcSEcCtD
Regorafenib—Rash—Mitoxantrone—prostate cancer	4.33e-05	0.000429	CcSEcCtD
Regorafenib—Dermatitis—Mitoxantrone—prostate cancer	4.32e-05	0.000428	CcSEcCtD
Regorafenib—Headache—Mitoxantrone—prostate cancer	4.3e-05	0.000426	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—prostate cancer	4.26e-05	0.000422	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.24e-05	0.00042	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—prostate cancer	4.19e-05	0.000415	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—prostate cancer	4.18e-05	0.000414	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—prostate cancer	4.17e-05	0.000413	CcSEcCtD
Regorafenib—Decreased appetite—Docetaxel—prostate cancer	4.12e-05	0.000409	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—prostate cancer	4.12e-05	0.000408	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Docetaxel—prostate cancer	4.1e-05	0.000406	CcSEcCtD
Regorafenib—Asthenia—Etoposide—prostate cancer	4.1e-05	0.000406	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—prostate cancer	4.1e-05	0.000406	CcSEcCtD
Regorafenib—Fatigue—Docetaxel—prostate cancer	4.09e-05	0.000405	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—prostate cancer	4.09e-05	0.000405	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—prostate cancer	4.09e-05	0.000405	CcSEcCtD
Regorafenib—Nausea—Mitoxantrone—prostate cancer	4.08e-05	0.000404	CcSEcCtD
Regorafenib—Infection—Prednisone—prostate cancer	4.07e-05	0.000403	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—prostate cancer	4.06e-05	0.000402	CcSEcCtD
Regorafenib—Pain—Docetaxel—prostate cancer	4.06e-05	0.000402	CcSEcCtD
Regorafenib—Nervous system disorder—Prednisone—prostate cancer	4.01e-05	0.000397	CcSEcCtD
Regorafenib—Decreased appetite—Capecitabine—prostate cancer	3.99e-05	0.000396	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—prostate cancer	3.98e-05	0.000394	CcSEcCtD
Regorafenib—Skin disorder—Prednisone—prostate cancer	3.97e-05	0.000394	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Capecitabine—prostate cancer	3.97e-05	0.000393	CcSEcCtD
Regorafenib—Fatigue—Capecitabine—prostate cancer	3.96e-05	0.000392	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—prostate cancer	3.94e-05	0.00039	CcSEcCtD
Regorafenib—Pain—Capecitabine—prostate cancer	3.93e-05	0.000389	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—prostate cancer	3.92e-05	0.000388	CcSEcCtD
Regorafenib—Diarrhoea—Etoposide—prostate cancer	3.91e-05	0.000387	CcSEcCtD
Regorafenib—Gastrointestinal pain—Docetaxel—prostate cancer	3.88e-05	0.000384	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—prostate cancer	3.87e-05	0.000383	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—prostate cancer	3.78e-05	0.000375	CcSEcCtD
Regorafenib—Gastrointestinal pain—Capecitabine—prostate cancer	3.76e-05	0.000372	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—prostate cancer	3.76e-05	0.000372	CcSEcCtD
Regorafenib—Abdominal pain—Docetaxel—prostate cancer	3.75e-05	0.000372	CcSEcCtD
Regorafenib—Body temperature increased—Docetaxel—prostate cancer	3.75e-05	0.000372	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—prostate cancer	3.68e-05	0.000365	CcSEcCtD
Regorafenib—Abdominal pain—Capecitabine—prostate cancer	3.63e-05	0.00036	CcSEcCtD
Regorafenib—Body temperature increased—Capecitabine—prostate cancer	3.63e-05	0.00036	CcSEcCtD
Regorafenib—Vomiting—Etoposide—prostate cancer	3.63e-05	0.00036	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—prostate cancer	3.63e-05	0.000359	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—prostate cancer	3.62e-05	0.000359	CcSEcCtD
Regorafenib—Rash—Etoposide—prostate cancer	3.6e-05	0.000357	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—prostate cancer	3.6e-05	0.000356	CcSEcCtD
Regorafenib—Headache—Etoposide—prostate cancer	3.58e-05	0.000354	CcSEcCtD
Regorafenib—Decreased appetite—Prednisone—prostate cancer	3.56e-05	0.000352	CcSEcCtD
Regorafenib—Fatigue—Prednisone—prostate cancer	3.53e-05	0.000349	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—prostate cancer	3.51e-05	0.000348	CcSEcCtD
Regorafenib—Asthenia—Docetaxel—prostate cancer	3.4e-05	0.000337	CcSEcCtD
Regorafenib—Nausea—Etoposide—prostate cancer	3.39e-05	0.000336	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—prostate cancer	3.39e-05	0.000335	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—prostate cancer	3.35e-05	0.000332	CcSEcCtD
Regorafenib—Gastrointestinal pain—Prednisone—prostate cancer	3.35e-05	0.000331	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.32e-05	0.000328	CcSEcCtD
Regorafenib—Asthenia—Capecitabine—prostate cancer	3.3e-05	0.000326	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—prostate cancer	3.27e-05	0.000323	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—prostate cancer	3.25e-05	0.000322	CcSEcCtD
Regorafenib—Diarrhoea—Docetaxel—prostate cancer	3.25e-05	0.000322	CcSEcCtD
Regorafenib—Body temperature increased—Prednisone—prostate cancer	3.23e-05	0.00032	CcSEcCtD
Regorafenib—Abdominal pain—Prednisone—prostate cancer	3.23e-05	0.00032	CcSEcCtD
Regorafenib—Infection—Epirubicin—prostate cancer	3.18e-05	0.000315	CcSEcCtD
Regorafenib—Diarrhoea—Capecitabine—prostate cancer	3.14e-05	0.000311	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—prostate cancer	3.14e-05	0.000311	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—prostate cancer	3.13e-05	0.00031	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—prostate cancer	3.13e-05	0.00031	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—prostate cancer	3.11e-05	0.000308	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.07e-05	0.000304	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—prostate cancer	3.02e-05	0.000299	CcSEcCtD
Regorafenib—Vomiting—Docetaxel—prostate cancer	3.02e-05	0.000299	CcSEcCtD
Regorafenib—Rash—Docetaxel—prostate cancer	2.99e-05	0.000296	CcSEcCtD
Regorafenib—Dermatitis—Docetaxel—prostate cancer	2.99e-05	0.000296	CcSEcCtD
Regorafenib—Headache—Docetaxel—prostate cancer	2.97e-05	0.000294	CcSEcCtD
Regorafenib—Infection—Doxorubicin—prostate cancer	2.94e-05	0.000291	CcSEcCtD
Regorafenib—Asthenia—Prednisone—prostate cancer	2.94e-05	0.000291	CcSEcCtD
Regorafenib—Vomiting—Capecitabine—prostate cancer	2.92e-05	0.000289	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—prostate cancer	2.9e-05	0.000288	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—prostate cancer	2.9e-05	0.000287	CcSEcCtD
Regorafenib—Rash—Capecitabine—prostate cancer	2.9e-05	0.000287	CcSEcCtD
Regorafenib—Dermatitis—Capecitabine—prostate cancer	2.89e-05	0.000287	CcSEcCtD
Regorafenib—Headache—Capecitabine—prostate cancer	2.88e-05	0.000285	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—prostate cancer	2.88e-05	0.000285	CcSEcCtD
Regorafenib—Nausea—Docetaxel—prostate cancer	2.82e-05	0.000279	CcSEcCtD
Regorafenib—Diarrhoea—Prednisone—prostate cancer	2.8e-05	0.000277	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—prostate cancer	2.78e-05	0.000276	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—prostate cancer	2.76e-05	0.000274	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—prostate cancer	2.76e-05	0.000273	CcSEcCtD
Regorafenib—Pain—Epirubicin—prostate cancer	2.74e-05	0.000271	CcSEcCtD
Regorafenib—Nausea—Capecitabine—prostate cancer	2.73e-05	0.00027	CcSEcCtD
Regorafenib—Gastrointestinal pain—Epirubicin—prostate cancer	2.62e-05	0.000259	CcSEcCtD
Regorafenib—Vomiting—Prednisone—prostate cancer	2.6e-05	0.000258	CcSEcCtD
Regorafenib—Rash—Prednisone—prostate cancer	2.58e-05	0.000256	CcSEcCtD
Regorafenib—Dermatitis—Prednisone—prostate cancer	2.58e-05	0.000255	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—prostate cancer	2.57e-05	0.000255	CcSEcCtD
Regorafenib—Headache—Prednisone—prostate cancer	2.56e-05	0.000254	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.56e-05	0.000253	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—prostate cancer	2.55e-05	0.000253	CcSEcCtD
Regorafenib—Pain—Doxorubicin—prostate cancer	2.53e-05	0.000251	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—prostate cancer	2.53e-05	0.000251	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—prostate cancer	2.53e-05	0.000251	CcSEcCtD
Regorafenib—Nausea—Prednisone—prostate cancer	2.43e-05	0.000241	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—prostate cancer	2.42e-05	0.00024	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—prostate cancer	2.34e-05	0.000232	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—prostate cancer	2.34e-05	0.000232	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—prostate cancer	2.3e-05	0.000227	CcSEcCtD
Regorafenib—Diarrhoea—Epirubicin—prostate cancer	2.19e-05	0.000217	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—prostate cancer	2.12e-05	0.00021	CcSEcCtD
Regorafenib—Vomiting—Epirubicin—prostate cancer	2.03e-05	0.000202	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—prostate cancer	2.03e-05	0.000201	CcSEcCtD
Regorafenib—Rash—Epirubicin—prostate cancer	2.02e-05	0.0002	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—prostate cancer	2.02e-05	0.0002	CcSEcCtD
Regorafenib—Headache—Epirubicin—prostate cancer	2e-05	0.000199	CcSEcCtD
Regorafenib—Nausea—Epirubicin—prostate cancer	1.9e-05	0.000188	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—prostate cancer	1.88e-05	0.000186	CcSEcCtD
Regorafenib—Rash—Doxorubicin—prostate cancer	1.87e-05	0.000185	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—prostate cancer	1.87e-05	0.000185	CcSEcCtD
Regorafenib—Headache—Doxorubicin—prostate cancer	1.86e-05	0.000184	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—prostate cancer	1.76e-05	0.000174	CcSEcCtD
Regorafenib—CYP2C8—Metabolism—MTHFR—prostate cancer	4.96e-07	3.69e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—prostate cancer	4.96e-07	3.69e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—prostate cancer	4.95e-07	3.68e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TYMS—prostate cancer	4.95e-07	3.68e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—prostate cancer	4.94e-07	3.67e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SRC—prostate cancer	4.94e-07	3.67e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CB—prostate cancer	4.93e-07	3.67e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SRC—prostate cancer	4.92e-07	3.66e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CG—prostate cancer	4.92e-07	3.66e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—LPL—prostate cancer	4.92e-07	3.66e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CTNNB1—prostate cancer	4.91e-07	3.65e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ITPR1—prostate cancer	4.89e-07	3.64e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTM1—prostate cancer	4.89e-07	3.64e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HPGDS—prostate cancer	4.88e-07	3.63e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARA—prostate cancer	4.87e-07	3.62e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2C19—prostate cancer	4.85e-07	3.6e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—prostate cancer	4.82e-07	3.58e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—prostate cancer	4.81e-07	3.58e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.81e-07	3.58e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—prostate cancer	4.81e-07	3.58e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—LPL—prostate cancer	4.8e-07	3.57e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—prostate cancer	4.8e-07	3.57e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1A—prostate cancer	4.79e-07	3.57e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—prostate cancer	4.78e-07	3.56e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—prostate cancer	4.78e-07	3.56e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—prostate cancer	4.78e-07	3.55e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—prostate cancer	4.76e-07	3.54e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP1A1—prostate cancer	4.75e-07	3.53e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—prostate cancer	4.75e-07	3.53e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—prostate cancer	4.75e-07	3.53e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—prostate cancer	4.75e-07	3.53e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—prostate cancer	4.75e-07	3.53e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—prostate cancer	4.74e-07	3.53e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—prostate cancer	4.74e-07	3.52e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFB1—prostate cancer	4.74e-07	3.52e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—prostate cancer	4.73e-07	3.52e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—prostate cancer	4.73e-07	3.52e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ACHE—prostate cancer	4.73e-07	3.52e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTT1—prostate cancer	4.73e-07	3.52e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ERCC2—prostate cancer	4.71e-07	3.5e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—prostate cancer	4.7e-07	3.5e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.68e-07	3.48e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—prostate cancer	4.68e-07	3.48e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—prostate cancer	4.66e-07	3.47e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—INS—prostate cancer	4.66e-07	3.47e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—prostate cancer	4.65e-07	3.46e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFB1—prostate cancer	4.65e-07	3.46e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—prostate cancer	4.64e-07	3.45e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP1A1—prostate cancer	4.64e-07	3.45e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—prostate cancer	4.63e-07	3.44e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TYMS—prostate cancer	4.62e-07	3.44e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—prostate cancer	4.62e-07	3.44e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—prostate cancer	4.62e-07	3.43e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ERCC2—prostate cancer	4.6e-07	3.42e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CAV1—prostate cancer	4.58e-07	3.4e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTM1—prostate cancer	4.57e-07	3.4e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CREBBP—prostate cancer	4.57e-07	3.4e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EP300—prostate cancer	4.56e-07	3.39e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—prostate cancer	4.56e-07	3.39e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.55e-07	3.38e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—prostate cancer	4.54e-07	3.38e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—prostate cancer	4.53e-07	3.37e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PRKACB—prostate cancer	4.53e-07	3.37e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—prostate cancer	4.52e-07	3.36e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—prostate cancer	4.51e-07	3.35e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—prostate cancer	4.5e-07	3.35e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—LPL—prostate cancer	4.49e-07	3.34e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.48e-07	3.33e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—prostate cancer	4.45e-07	3.31e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SRC—prostate cancer	4.44e-07	3.3e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—prostate cancer	4.43e-07	3.29e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—prostate cancer	4.42e-07	3.29e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—prostate cancer	4.42e-07	3.29e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFB1—prostate cancer	4.41e-07	3.28e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—prostate cancer	4.41e-07	3.28e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—prostate cancer	4.41e-07	3.28e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFB1—prostate cancer	4.4e-07	3.27e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—prostate cancer	4.39e-07	3.26e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—prostate cancer	4.39e-07	3.26e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—prostate cancer	4.38e-07	3.26e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—prostate cancer	4.37e-07	3.25e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.37e-07	3.25e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—prostate cancer	4.37e-07	3.25e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—prostate cancer	4.35e-07	3.23e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARA—prostate cancer	4.34e-07	3.23e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP1A1—prostate cancer	4.33e-07	3.22e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CD—prostate cancer	4.33e-07	3.22e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—prostate cancer	4.33e-07	3.22e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—prostate cancer	4.32e-07	3.21e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—prostate cancer	4.32e-07	3.21e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—prostate cancer	4.32e-07	3.21e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—prostate cancer	4.31e-07	3.2e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ERCC2—prostate cancer	4.3e-07	3.19e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—prostate cancer	4.3e-07	3.19e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—prostate cancer	4.29e-07	3.19e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—prostate cancer	4.28e-07	3.18e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1A—prostate cancer	4.27e-07	3.18e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—prostate cancer	4.27e-07	3.17e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NCOA2—prostate cancer	4.27e-07	3.17e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—prostate cancer	4.26e-07	3.17e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—prostate cancer	4.26e-07	3.17e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—prostate cancer	4.25e-07	3.16e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—EP300—prostate cancer	4.24e-07	3.15e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARA—prostate cancer	4.24e-07	3.15e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—prostate cancer	4.21e-07	3.13e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—prostate cancer	4.17e-07	3.1e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CG—prostate cancer	4.17e-07	3.1e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—prostate cancer	4.16e-07	3.09e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—prostate cancer	4.16e-07	3.09e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—prostate cancer	4.12e-07	3.06e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—prostate cancer	4.09e-07	3.04e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NOS3—prostate cancer	4.09e-07	3.04e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAV1—prostate cancer	4.09e-07	3.04e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—prostate cancer	4.08e-07	3.03e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.07e-07	3.03e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EP300—prostate cancer	4.07e-07	3.02e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—prostate cancer	4.04e-07	3e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—prostate cancer	4.03e-07	3e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAV1—prostate cancer	3.99e-07	2.97e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.98e-07	2.96e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—prostate cancer	3.98e-07	2.96e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFB1—prostate cancer	3.97e-07	2.95e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARA—prostate cancer	3.96e-07	2.95e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—prostate cancer	3.96e-07	2.94e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SRC—prostate cancer	3.95e-07	2.94e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—INS—prostate cancer	3.95e-07	2.93e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—prostate cancer	3.94e-07	2.93e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NQO1—prostate cancer	3.93e-07	2.92e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.9e-07	2.9e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—prostate cancer	3.9e-07	2.9e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—prostate cancer	3.89e-07	2.89e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—prostate cancer	3.89e-07	2.89e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TH—prostate cancer	3.87e-07	2.88e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CREBBP—prostate cancer	3.87e-07	2.87e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—prostate cancer	3.85e-07	2.86e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—prostate cancer	3.85e-07	2.86e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—prostate cancer	3.83e-07	2.85e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—prostate cancer	3.81e-07	2.84e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—prostate cancer	3.8e-07	2.83e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—prostate cancer	3.8e-07	2.83e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CB—prostate cancer	3.77e-07	2.81e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.77e-07	2.8e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—prostate cancer	3.76e-07	2.79e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—prostate cancer	3.75e-07	2.79e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—prostate cancer	3.74e-07	2.78e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAV1—prostate cancer	3.72e-07	2.77e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CG—prostate cancer	3.72e-07	2.77e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—prostate cancer	3.7e-07	2.75e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—prostate cancer	3.7e-07	2.75e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—prostate cancer	3.67e-07	2.73e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CD—prostate cancer	3.66e-07	2.73e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GGT1—prostate cancer	3.65e-07	2.71e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—prostate cancer	3.63e-07	2.7e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CG—prostate cancer	3.63e-07	2.7e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—prostate cancer	3.62e-07	2.69e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NCOA1—prostate cancer	3.6e-07	2.67e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—prostate cancer	3.59e-07	2.67e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—prostate cancer	3.57e-07	2.65e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.56e-07	2.65e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—prostate cancer	3.55e-07	2.64e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.54e-07	2.64e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—prostate cancer	3.54e-07	2.64e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFB1—prostate cancer	3.53e-07	2.63e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—INS—prostate cancer	3.52e-07	2.62e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—prostate cancer	3.51e-07	2.61e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—prostate cancer	3.5e-07	2.61e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—prostate cancer	3.47e-07	2.58e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NOS3—prostate cancer	3.46e-07	2.57e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CREBBP—prostate cancer	3.45e-07	2.57e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—INS—prostate cancer	3.44e-07	2.56e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—RXRA—prostate cancer	3.42e-07	2.54e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CG—prostate cancer	3.39e-07	2.52e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—prostate cancer	3.37e-07	2.51e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CREBBP—prostate cancer	3.37e-07	2.5e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—prostate cancer	3.33e-07	2.47e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—prostate cancer	3.32e-07	2.47e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—COMT—prostate cancer	3.29e-07	2.45e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—prostate cancer	3.29e-07	2.45e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTP1—prostate cancer	3.28e-07	2.44e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—prostate cancer	3.27e-07	2.43e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CD—prostate cancer	3.27e-07	2.43e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—prostate cancer	3.26e-07	2.43e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—prostate cancer	3.26e-07	2.42e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—prostate cancer	3.23e-07	2.4e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ITPR1—prostate cancer	3.23e-07	2.4e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—INS—prostate cancer	3.21e-07	2.39e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CB—prostate cancer	3.19e-07	2.38e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CD—prostate cancer	3.19e-07	2.37e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—prostate cancer	3.17e-07	2.35e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CREBBP—prostate cancer	3.15e-07	2.34e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—prostate cancer	3.14e-07	2.33e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—EP300—prostate cancer	3.11e-07	2.31e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NOS3—prostate cancer	3.09e-07	2.3e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—prostate cancer	3.07e-07	2.28e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—prostate cancer	3.06e-07	2.28e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TYMS—prostate cancer	3.05e-07	2.27e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—prostate cancer	3.02e-07	2.25e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—prostate cancer	3.02e-07	2.25e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NOS3—prostate cancer	3.01e-07	2.24e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTM1—prostate cancer	3.01e-07	2.24e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—prostate cancer	3.01e-07	2.24e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—prostate cancer	2.99e-07	2.22e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.98e-07	2.22e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—LPL—prostate cancer	2.96e-07	2.2e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—prostate cancer	2.91e-07	2.16e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.86e-07	2.12e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CB—prostate cancer	2.85e-07	2.12e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ERCC2—prostate cancer	2.83e-07	2.11e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—prostate cancer	2.83e-07	2.1e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NOS3—prostate cancer	2.82e-07	2.09e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CB—prostate cancer	2.78e-07	2.07e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—prostate cancer	2.76e-07	2.05e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—prostate cancer	2.76e-07	2.05e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—prostate cancer	2.76e-07	2.05e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—prostate cancer	2.66e-07	1.98e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—prostate cancer	2.66e-07	1.98e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—EP300—prostate cancer	2.63e-07	1.96e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARA—prostate cancer	2.61e-07	1.94e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CB—prostate cancer	2.6e-07	1.93e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—prostate cancer	2.58e-07	1.92e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—prostate cancer	2.56e-07	1.91e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—prostate cancer	2.46e-07	1.83e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—prostate cancer	2.46e-07	1.83e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAV1—prostate cancer	2.46e-07	1.83e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—prostate cancer	2.4e-07	1.79e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—EP300—prostate cancer	2.35e-07	1.75e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—prostate cancer	2.3e-07	1.71e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—EP300—prostate cancer	2.29e-07	1.71e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—prostate cancer	2.25e-07	1.67e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.24e-07	1.66e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—EP300—prostate cancer	2.14e-07	1.59e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—INS—prostate cancer	2.12e-07	1.58e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CREBBP—prostate cancer	2.07e-07	1.54e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.97e-07	1.46e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—prostate cancer	1.95e-07	1.45e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—prostate cancer	1.88e-07	1.4e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NOS3—prostate cancer	1.86e-07	1.38e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.74e-07	1.29e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.71e-07	1.28e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—prostate cancer	1.7e-07	1.26e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—prostate cancer	1.7e-07	1.26e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—prostate cancer	1.59e-07	1.18e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.58e-07	1.18e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—prostate cancer	1.48e-07	1.1e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—prostate cancer	1.42e-07	1.06e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—EP300—prostate cancer	1.41e-07	1.05e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—prostate cancer	1.39e-07	1.03e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—prostate cancer	1.29e-07	9.63e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.05e-07	7.77e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—prostate cancer	8.54e-08	6.35e-07	CbGpPWpGaD
